Gerd Bendas

Professor at the Pharmaceutical Institute, University of Bonn, specializing in oncological research focused on chemoresistance mechanisms and tumor microenvironment interactions. Key research examines platelet-tumor cell interactions and heparin-based therapeutic strategies.

Research investigates molecular pathways of drug resistance in breast and ovarian cancers, with emphasis on integrin-mediated signaling and extracellular matrix interactions. Develops heparin derivatives and synthetic mimetics to inhibit metastasis.

Studies platelet-mediated immunomodulation in cancer and explores glycobiology approaches to disrupt tumor-host interactions. Recent publications focus on heparan sulfate modifications and anticoagulant therapies.